Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 135976, 4 pages
http://dx.doi.org/10.1155/2015/135976
Case Report

Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis

1Department of Medical Oncology, Medical School, University of Ioannina, 45110 Ioannina, Greece
2Department of Neurology, Medical School, University of Ioannina, 45110 Ioannina, Greece
3Department of Pathology, Medical School, University of Ioannina, 45110 Ioannina, Greece
4Department of Radiology, Medical School, University of Ioannina, 45110 Ioannina, Greece

Received 11 December 2014; Accepted 16 March 2015

Academic Editor: Francesca Micci

Copyright © 2015 Stergios Boussios et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization and Multiple Sclerosis International Federation, Atlas: Multiple Sclerosis Resources in the World 2008, WHO Library Cataloguing-in-Publication Data, 2009, http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf.
  2. N. Pavlidis and K. Fizazi, “Cancer of unknown primary (CUP),” Critical Reviews in Oncology/Hematology, vol. 54, no. 3, pp. 243–250, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Levi, V.-C. Te, G. Erler, L. Randimbison, and C. La Vecchia, “Epidemiology of unknown primary tumours,” European Journal of Cancer, vol. 38, no. 13, pp. 1810–1812, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Pavlidis, “Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets,” Annals of Oncology, vol. 23, supplement 10, pp. x282–x285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. N. M. Nielsen, K. Rostgaard, S. Rasmussen et al., “Cancer risk among patients with multiple sclerosis: a population-based register study,” International Journal of Cancer, vol. 118, no. 4, pp. 979–984, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. L. Di Patre, V. Castillo, J. Delavelle, S. Vuillemoz, F. Picard, and T. Landis, “‘Tumor-mimicking’ multiple sclerosis,” Clinical Neuropathology, vol. 22, no. 5, pp. 235–239, 2003. View at Google Scholar · View at Scopus
  7. D. W. Giang, K. R. Poduri, T. A. Eskin et al., “Multiple sclerosis masquerading as a mass lesion,” Neuroradiology, vol. 34, no. 2, pp. 150–154, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Kingwell, C. Bajdik, N. Phillips et al., “Cancer risk in multiple sclerosis: findings from British Columbia, Canada,” Brain, vol. 135, no. 10, pp. 2973–2979, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. F. Fois, C. J. Wotton, D. Yeates, M. R. Turner, and M. J. Goldacre, “Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 2, pp. 215–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Bahmanyar, S. M. Montgomery, J. Hillert, A. Ekbom, and T. Olsson, “Cancer risk among patients with multiple sclerosis and their parents,” Neurology, vol. 72, no. 13, pp. 1170–1177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M.-L. Sumelahti, E. Pukkala, and M. Hakama, “Cancer incidence in multiple sclerosis: a 35-year follow-up,” Neuroepidemiology, vol. 23, no. 5, pp. 224–227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Midgard, E. Glattre, M. Grønning, T. Riise, A. Edland, and H. Nyland, “Multiple sclerosis and cancer in Norway. A retrospective cohort study,” Acta Neurologica Scandinavica, vol. 93, no. 6, pp. 411–415, 1996. View at Google Scholar · View at Scopus
  13. H. Moller, R. W. Kneller, J. D. Boice Jr., and J. H. Olsen, “Cancer incidence following hospitalization for multiple sclerosis in Denmark,” Acta Neurologica Scandinavica, vol. 84, no. 3, pp. 214–220, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Lebrun, M. Debouverie, P. Vermersch et al., “Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 3, pp. 399–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Landgren, O. Landgren, G. Gridley, G. M. Dores, M. S. Linet, and L. M. Morton, “Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans,” Cancer, vol. 117, no. 6, pp. 1163–1171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Thun, S. Jane Henley, and C. Patrono, “Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues,” Journal of the National Cancer Institute, vol. 94, no. 4, pp. 252–266, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. H. T. Sørensen, S. Friis, B. Nørgård et al., “Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study,” British Journal of Cancer, vol. 88, no. 11, pp. 1687–1692, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. S. Langman, K. K. Cheng, E. A. Gilman, and R. J. Lancashire, “Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database,” British Medical Journal, vol. 320, no. 7250, pp. 1642–1646, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Midgard, E. Glattre, M. Grønning, T. Riise, A. Edland, and H. Nyland, “Multiple sclerosis and cancer in Norway. A retrospective cohort study,” Acta Neurologica Scandinavica, vol. 93, no. 6, pp. 411–415, 1996. View at Google Scholar
  20. A. E. Handel, A. Joseph, and S. V. Ramagopalan, “Multiple sclerosis and lung cancer: an unexpected inverse association,” QJM, vol. 103, no. 8, Article ID hcq071, pp. 625–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. The INFB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, “Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial,” Neurology, vol. 45, no. 7, pp. 1277–1285, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG),” Annals of Neurology, vol. 39, no. 3, pp. 285–294, 1996. View at Publisher · View at Google Scholar
  23. “Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group,” The Lancet, vol. 352, no. 9139, pp. 1498–1504, 1998.
  24. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Schrempf and T. Ziemssen, “Glatiramer acetate: mechanisms of action in multiple sclerosis,” Autoimmunity Reviews, vol. 6, no. 7, pp. 469–475, 2007. View at Publisher · View at Google Scholar · View at Scopus